TITLE

A 15-μg dose of unadjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in healthy adults within 21 days

AUTHOR(S)
Granwehr, Bruno
PUB. DATE
January 2010
SOURCE
ACP Journal Club;1/19/2010, Vol. 152 Issue 1, p8
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study conducted by researcher M.E. Greenberg and colleagues to know the immunogenicity and safety of 2 different doses of a monovalent, unadjuvanted influenza A (H1N1) 2009 vaccine. Randomized controlled trial has found 33% of persons in the 15-mg group and 30% in the 30-mg group had HI antibody titers 1:40 before vaccination.
ACCESSION #
48180245

 

Related Articles

  • Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. Treanor, John J.; Campbell, James D.; Zangwill, Kenneth M.; Rowe, Thomas; Wolff, Mark // New England Journal of Medicine;3/30/2006, Vol. 354 Issue 13, p1343 

    Background: Influenza A (H5N1) viruses could cause a severe worldwide epidemic, with high attack rates, large numbers of deaths and hospitalizations, and wide disruption. Effective vaccines against these viruses in humans are urgently needed. Methods: We conducted a multicenter, double-blind...

  • Inactivated Quadrivalent Split-Virus Seasonal Influenza Vaccine (Fluarix Quadrivalent): A Review of Its Use in the Prevention of Disease Caused by Influenza A and B. McKeage, Kate // Drugs;2013, Vol. 73 Issue 14, p1587 

    The inactivated quadrivalent split-virus seasonal influenza vaccine [Fluarix quadrivalent, manufactured in Dresden (D-QIV)] contains 15 μg haemagglutinin from each of the four influenza virus strains expected to circulate in the upcoming influenza season. Unlike seasonal trivalent influenza...

  • Antibodies Cross-Reactive to Influenza A (H3N2) Variant Virus and Impact of 2010-11 Seasonal Influenza Vaccine on Cross-Reactive Antibodies -- United States. Branch, Alicia; Veguilla, Vic; Gillis, Eric; Reed, Carrie; Noland, Heather; Thomas, Leilani; Browning, Peter; Fry, Amanda Balish Alicia; Cox, Nancy; Katz, Jacqueline M.; Hancock, Kathy // MMWR: Morbidity & Mortality Weekly Report;4/13/2012, Vol. 61 Issue 14, p237 

    The article focuses on the influenza A (H3N2)v virus that infected twelve persons in the U.S. in 2011, mostly children below 10 years. Data show that children in this age bracket had few or no cross-reactive antibodies to A (H3N2)v virus, but there were cross-reactive antibodies to the virus in...

  • Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. Kieninger, Dorothee; Sheldon, Eric; Wen-Yuan Lin; Chong-Jen Yu; Bayas, Jose M.; Gabor, Julian J.; Esen, Meral; Fernandez Roure, Jose Luis; Narejos Perez, Silvia; Alvarez Sanchez, Carmen; Yang Feng; Claeys, Carine; Peeters, Mathieu; Innis, Bruce L.; Jain, Varsha; Lin, Wen-Yuan; Yu, Chong-Jen; Feng, Yang // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Two antigenically distinct influenza B lineages have co-circulated since the 1980s, yet inactivated trivalent influenza vaccines (TIVs) include strains of influenza A/H1N1, A/H3N2, and only one influenza B from either the Victoria or Yamagata lineage. This means that...

  • Need for Speed: FDA Pushes for Vaccine Approval Ahead of Data. Young, Donna // BioWorld Today;7/24/2009, Vol. 20 Issue 141, p3 

    This article reports on the plan of the U.S. Food and Drug Administration (FDA) in 2009 to approve a vaccine against the H1N1 swine-origin influenza A virus without waiting for data from required clinical trials in 2009. Advisers of the FDA supported the plan. The agency announced the plan in...

  • Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A (H1N1) pdm 2009 infection. Yamamoto, Takehisa; Mizoguchi, Yoshimi; Kaneno, Hiroshi; Yamamoto, Katsusuke; Inoue, Yutaka; Kawashima, Hisashi; Kase, Tetsuo; Shimotsuji, Tsunesuke // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2013, Vol. 19 Issue 5, p833 

    The clinical severity of the 2009 pandemic H1N1 influenza (H1N1 pdm09) was thought to be related to the difference between the amount of viral load and condition of the host immune response. We investigated the role of serum levels of IgG and its subclasses in clinical severity using the data...

  • Avian-flu vaccine trials. Ahmad, Sharon // Nature Reviews Immunology;Aug2006, Vol. 6 Issue 8, p567 

    The article focuses on the plan of British biotechnology company PowerMed to conduct the first clinical trials for its experimental vaccine against the lethal H5N1 subtype of the avian influenza A virus. The company's vaccine has only been tested in animals so far. Components of the PowerMed...

  • Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults. Crank, Michelle C.; Gordon, Ingelise J.; Yamshchikov, Galina V.; Sitar, Sandra; Hu, Zonghui; Enama, Mary E.; Holman, LaSonji A.; Bailer, Robert T.; Pearce, Melissa B.; Koup, Richard A.; Mascola, John R.; Nabel, Gary J.; Tumpey, Terrence M.; Schwartz, Richard M.; Graham, Barney S.; Ledgerwood, Julie E.; null, null // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We describe the rapid production and clinical...

  • Reacciones Adversas de la Vacunación contra la Influenza Humana en adultos jóvenes de la Araucanía en Abril -- Mayo 2010. Salinas, G. Yasna; Rivas, V. Daniela; Urbina, V. Pablo; Ríos, O. Simón; Gayoso, N. Roxana // Revista ANACEM;2010, Vol. 4 Issue 2, p65 

    ABSTRACT INTRODUCTION: In 2009 the World was shocked by the influenza A (H1N1) pandemia. A huge debate has taken place for the convenience of the anti A(H1N1) vaccination in relation to the few clinical trials and the adverse reactions generated by other vaccines produced under the same process....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics